RT Journal Article
SR Electronic
T1 International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
JF Pharmacological Reviews
JO Pharmacol Rev
FD American Society for Pharmacology and Experimental Therapeutics
SP 763
OP 835
DO 10.1124/pr.117.015388
VO 70
IS 4
A1 Thomas Günther
A1 Giovanni Tulipano
A1 Pascal Dournaud
A1 Corinne Bousquet
A1 Zsolt Csaba
A1 Hans-Jürgen Kreienkamp
A1 Amelie Lupp
A1 Márta Korbonits
A1 Justo P. Castaño
A1 Hans-Jürgen Wester
A1 Michael Culler
A1 Shlomo Melmed
A1 Stefan Schulz
A2 Eliot H. Ohlstein
YR 2018
UL http://pharmrev.aspetjournals.org/content/70/4/763.abstract
AB Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its physiologic functions are mediated by five G protein–coupled receptors (GPCRs) called somatostatin receptor (SST)1–5. These five receptors share common structural features and signaling mechanisms but differ in their cellular and subcellular localization and mode of regulation. SST2 and SST5 receptors have evolved as primary targets for pharmacological treatment of pituitary adenomas and neuroendocrine tumors. In addition, SST2 is a prototypical GPCR for the development of peptide-based radiopharmaceuticals for diagnostic and therapeutic interventions. This review article summarizes findings published in the last 25 years on the physiology, pharmacology, and clinical applications related to SSTs. We also discuss potential future developments and propose a new nomenclature.